Sotera Health Co.
- SHC · Nasdaq
- Services-Misc Health & Allied Services, NEC
- Broadview Heights, OH
- 3,000 employees
- CIK 0001822479
Updated from SEC filings through
Top things to know
Executives
- Alton Shader Chief Executive Officer 8-K, 2026-11-03
- Jonathan M. Lyons Sr. Vice President, CFO 4, 2026-08-07
- Jonathan (Jon) Lyons Senior Vice President and Chief Financial Officer 10-K, 2026-02-24
- Michael P. Rutz President of Sterigenics 4, 2026-08-11
- Michael (Mike) P. Rutz President of Sterigenics 10-K, 2026-02-24
- Alexander (Alex) Dimitrief Senior Vice President and General Counsel 10-K, 2026-02-24
What leadership is saying
“We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
Sotera Health Co is a U.S. public company in services-misc health & allied services, nec (SIC 8090), headquartered in Broadview Heights, OH. It trades as SHC on Nasdaq. Revenue was $1.2B in the fiscal year ending December 31, 2025, +5.7% from the year before. It reported about 3,000 employees. Alton Shader is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.2B 10-K, 2026-02-24 | $1.1B 10-K, 2026-02-24 | $1.0B 10-K, 2026-02-24 | $1.0B 10-K, 2025-02-27 | $931M 10-K, 2024-02-27 |
| Operating income | Not on file | $298M 10-K, 2025-02-27 | $277M 10-K, 2025-02-27 | $248M 10-K, 2025-02-27 | $257M 10-K, 2024-02-27 |
| SG&A | $253M 10-K, 2026-02-24 | $243M 10-K, 2026-02-24 | $237M 10-K, 2026-02-24 | $246M 10-K, 2025-02-27 | $198M 10-K, 2024-02-27 |
| Net income | $77.9M 10-K, 2026-02-24 | $44.4M 10-K, 2026-02-24 | $51.4M 10-K, 2026-02-24 | -$234M 10-K, 2025-02-27 | $117M 10-K, 2024-02-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Alton Shader | Chief Executive Officer | 8-K, 2026-11-03 |
| Jonathan M. Lyons | Sr. Vice President, CFO | 4, 2026-08-07 |
| Jonathan Lyons | Board member (per proxy) bio: SVP, CFO | DEF 14A, 2026-04-08 |
| Jonathan (Jon) Lyons | Senior Vice President and Chief Financial Officer | 10-K, 2026-02-24 |
| Michael P. Rutz President of Sterigenics (a Sotera Health company) | President of Sterigenics | 4, 2026-08-11 |
| Michael (Mike) P. Rutz President of Sterigenics (a Sotera Health company) | President of Sterigenics | 10-K, 2026-02-24 |
| Alexander (Alex) Dimitrief | Senior Vice President and General Counsel | 10-K, 2026-02-24 |
 Michael B. Petras Jr. | Executive Chairman | 4, 2026-08-19 |
| Erika Ostrowski Senior Vice President, General Counsel and Corporate Secretary at Sotera Health | SVP, General Counsel and Sec. | 3, 2026-04-08 |
| Alexander Dimitrief | Former SVP, GC and Sec. | 4, 2026-04-02 |
| Christopher A. Simon | Board member (per proxy) bio: Director | DEF 14A, 2026-04-08 |
| Sean L. Cunningham | Board member (per proxy) bio: Director | DEF 14A, 2026-04-08 |
| Vincent K. Petrella | Board member (per proxy) bio: Lead Independent Director | DEF 14A, 2026-04-08 |
What Sotera Health Co does
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health ® . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 285.6 million (as of October 27, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Public float | $1.7B (as of June 30, 2025) | 10-K, February 24, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 3, 2026 |
| Latest proxy statement | Meeting May 21, 2026 (filed April 8, 2026) | DEF 14A, April 8, 2026 |
| Auditor | Ernst & Young LLP (Cleveland, Ohio) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 17, 2026 | Michael B. Petras Jr. Executive Chairman | Sale | 1,144,515 | $21.2M | Form 4, August 19, 2026 |
| August 7, 2026 | Michael P. Rutz President of Sterigenics | Sale | 150,000 | $2.8M | Form 4, August 11, 2026 |
| May 13, 2026 | Pincus XI-C LLC Warburg Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
| May 13, 2026 | Pincus &. Co. Warburg Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
| May 13, 2026 | Pincus Llc Warburg Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
| May 13, 2026 | Pincus Private Equity XI-C L.P. Warburg Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
| May 13, 2026 | Pincus Partners GP LLC Warburg Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
| May 13, 2026 | Pincus Partners (Cayman) L.P. Warburg II Director | Sale | 19,102,952 | $290M | Form 4, May 15, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-14
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-22
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-20
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-05-13
- Item 1.02 Termination of a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-06
- Item 8.01 Other events
- 8-K filed 2026-02-24
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Sotera Health Co
- What does Sotera Health Co do?
- In its own words, from Item 1 of its 10-K: "We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health ® . We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world."
- What is Sotera Health Co's revenue?
- $1.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 24, 2026.
- Is Sotera Health Co profitable?
- Sotera Health Co reported net income of $77.9M for the fiscal year ending December 31, 2025.
- How many employees does Sotera Health Co have?
- About 3,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Sotera Health Co?
- Alton Shader, Chief Executive Officer, as named in a 8-K filed November 3, 2026.
- Who is the CFO of Sotera Health Co?
- Jonathan M. Lyons, Sr. Vice President, CFO, as named in a 4 filed August 7, 2026.
- Where is Sotera Health Co headquartered?
- Broadview Heights, OH.
- What is Sotera Health Co's stock ticker?
- SHC on Nasdaq.
- What industry is Sotera Health Co in?
- Services-Misc Health & Allied Services, NEC, SIC code 8090.
- What is Sotera Health Co's website?
- soterahealth.com.
- When does Sotera Health Co report earnings next?
- December 2, 2026 at 11:00. Source: pg_future_events.
- Is Sotera Health Co a public company?
- Yes. Sotera Health Co files with the SEC under CIK 0001822479 and trades as SHC.
- Who audits Sotera Health Co?
- Ernst & Young LLP, Cleveland, Ohio, as named in its latest annual report (10-K).
- How many shares of Sotera Health Co are outstanding?
- 285.6 million shares as of October 27, 2026, from its 10-Q filed November 3, 2026.
- What is Sotera Health Co's public float?
- $1.7B as of June 30, 2025, as reported on the cover of its 10-K filed February 24, 2026.
- How many business segments does Sotera Health Co report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
- When is Sotera Health Co's annual shareholder meeting?
- May 21, 2026, per its proxy statement (DEF 14A) filed April 8, 2026.
- Have Sotera Health Co insiders traded stock recently?
- Since September 5, 2025, officers and directors reported 97 open-market sales worth about $20.9B and 0 purchases on Forms 4 and 5. The most recent: Michael B. Petras Jr. (Executive Chairman) sold 1,144,515 shares on August 17, 2026.